SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy - Wikidata - awgldk - TriplyDB

SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy

SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy

http://www.wikidata.org/entity/Q28271235

about

Spinal muscular atrophy The contribution of mouse models to understanding the pathogenesis of spinal muscular atrophy Molecular Mechanisms of Neurodegeneration in Spinal Muscular Atrophy 5p deletions: Current knowledge and future directions.Spinal muscular atrophy: from gene discovery to clinical trials Histone deacetylase inhibitors as potential treatment for spinal muscular atrophy Spinal muscular atrophy: development and implementation of potential treatments Applicability of histone deacetylase inhibition for the treatment of spinal muscular atrophy Histone Deacetylase (HDAC) Inhibitors - emerging roles in neuronal memory, learning, synaptic plasticity and neural regeneration The promise and perils of HDAC inhibitors in neurodegeneration Prolactin increases SMN expression and survival in a mouse model of severe spinal muscular atrophy via the STAT5 pathway.Systemic restoration of UBA1 ameliorates disease in spinal muscular atrophy Arrhythmia and cardiac defects are a feature of spinal muscular atrophy model mice.Selective Neuromuscular Denervation in Taiwanese Severe SMA Mouse Can Be Reversed by Morpholino Antisense Oligonucleotides Utility of survival motor neuron ELISA for spinal muscular atrophy clinical and preclinical analyses Postsymptomatic restoration of SMN rescues the disease phenotype in a mouse model of severe spinal muscular atrophy.Sodium vanadate combined with L-ascorbic acid delays disease progression, enhances motor performance, and ameliorates muscle atrophy and weakness in mice with spinal muscular atrophy.The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models.Pathological impact of SMN2 mis-splicing in adult SMA mice Protective effects of butyrate-based compounds on a mouse model for spinal muscular atrophy.Decreased microRNA levels lead to deleterious increases in neuronal M2 muscarinic receptors in Spinal Muscular Atrophy models Bioenergetic status modulates motor neuron vulnerability and pathogenesis in a zebrafish model of spinal muscular atrophy.Mouse survival motor neuron alleles that mimic SMN2 splicing and are inducible rescue embryonic lethality early in development but not late Spinal muscular atrophy: mechanisms and therapeutic strategies.Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model Analysis of the fibroblast growth factor system reveals alterations in a mouse model of spinal muscular atrophy Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy.Drug discovery and development for spinal muscular atrophy: lessons from screening approaches and future challenges for clinical development.A humanized Smn gene containing the SMN2 nucleotide alteration in exon 7 mimics SMN2 splicing and the SMA disease phenotype.Temporal requirement for high SMN expression in SMA mice New therapeutic approaches to spinal muscular atrophy.Therapeutic strategies for the treatment of spinal muscular atrophy.VPA response in SMA is suppressed by the fatty acid translocase CD36.SMN-inducing compounds for the treatment of spinal muscular atrophy.Spinal Muscular Atrophy Therapeutics: Where do we Stand?Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy.SMN regulates axonal local translation via miR-183/mTOR pathway Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug-like compounds Histone deacetylase inhibitor upregulates peroxisomal fatty acid oxidation and inhibits apoptotic cell death in abcd1-deficient glial cells.A cell system for phenotypic screening of modifiers of SMN2 gene expression and function.

P2860

Q21202863-CB7CDC92-6EBD-4C17-AD12-9739F0E95E98 Q24604444-C29BFD9B-82A1-4FAE-8B4F-AF83BF63D8F5 Q26752798-931654C3-DB89-4EF7-A286-6D8F7B5EA236 Q26800129-D53625DB-A080-440B-8247-CDEE5459A170 Q26824894-49BDAAF0-CCE2-461A-9BB3-C864B87AB8CE Q26828876-48BE0B05-26DD-4709-8697-4B6893AB441D Q26861377-CE3FCFBD-5C4F-49FE-8AFC-F62520638400 Q26864605-EDD2B22B-F447-4F3D-A267-3FDFDE613BEB Q28080593-D3DB4A94-E2E3-4F4E-BEB5-F6214119D2EE Q28087539-87DF8E2F-458D-42B5-BC64-C5B0BC2D66DA Q28243993-5FE9A154-9989-4161-AF7A-477CD0C14F06 Q28279022-E9344D2B-8BA7-4528-A2A9-54970D58F637 Q28289944-6203A597-67A9-4CD2-B372-5987708AE67C Q28551647-2D5B4330-C77B-496D-BDFC-75911D5ECBC5 Q28740896-CECEB3F7-D93C-477D-B41A-E2F119AF5F7F Q30503157-C491C756-FEB7-466D-B176-FD8F595CC557 Q30540653-B65DE418-8B5F-4E09-92AF-9382C4607025 Q30546337-D55EDCFD-4A1E-4EF6-95D6-809E5B4A4FA0 Q30551534-868385AE-92FC-49A4-B204-EAE16F6683CD Q30743508-2A43B5B0-1003-4ED5-9398-A19568E952E7 Q33627433-7ACA2356-B670-45B5-A032-893ADACFBE5C Q33638307-60E46DDE-E5AE-45A1-948A-08A151FB3A6D Q33797677-4E652099-285F-405E-98CC-7E2BDC096651 Q33871311-4F25669E-4C12-4547-AA0B-1E5718FD71AF Q34030144-C3C39ED0-C015-45E5-BF00-37F06CCB97A4 Q34163418-57D5CC0A-9754-4A29-9B5A-7B5340A6442D Q34168139-8E9A2A2A-4246-4FF0-B3BB-521EEE8B5E1E Q34172502-4AF8B48F-5CD6-49CF-98D8-818C949D2EE5 Q34184793-74184780-C065-4142-9820-4BF8496006BC Q34192528-C8908E82-4845-41AE-92C9-A46713D23A1D Q34237525-4A16567E-2CC4-4B77-A913-BB30F7A6039A Q34296140-8117DDB1-D154-4D45-9A76-FDC9B1BC9DE2 Q34306857-7EA0AEBA-75E6-477A-B4F1-4CE73B079116 Q34312156-E379CC06-9E61-4313-8C91-00A4AC52847E Q34460251-775C8150-5CCC-434B-862C-FD3B7217751C Q34540158-11B859C6-D731-4FA4-B435-F0A6C672A6AF Q34736851-4A930CE1-62B9-43B9-B298-7FF7155D6094 Q34760255-FEFB1E10-F3D8-4E71-B2BB-10E31C850204 Q34907267-19B4034C-2687-4CCB-A55C-E54B5C2D5DF4 Q34964785-9A666AE0-090C-42C9-B9EA-42EDDCB1E6CF

P2860

SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy

http://www.wikidata.org/entity/Q28271235

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy

@ast

SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy

@en

SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy

@nl

type

label

SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy

@ast

SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy

@en

SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy

@nl

prefLabel

SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy

@ast

SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy

@en

SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy

@nl

P1433

Q28271235-01E04A82-AE5E-4C4D-BEAE-104B797FDB59

P1476

Q28271235-8652B4F5-F4C2-423B-A5FA-4B4580762510

P2093

Q28271235-245D713B-74AA-4FEA-8D7C-B8D3E824E784

Q28271235-3C8C8741-E219-4BD8-B469-DD966671AB04

Q28271235-42A94501-C04B-4C1E-80B6-22F7DA2BD805

Q28271235-4542A1AC-E1A6-482E-A544-00C6E87AF95C

Q28271235-5B36BB48-183C-4D44-9438-3AC6745C6277

Q28271235-79871A62-ADC6-40C4-9A60-592193362D51

Q28271235-7DBC7B79-A88A-4256-8AE2-411108B1A9EC

Q28271235-83539280-2BE2-454B-969D-C9AFC23B2058

Q28271235-CC0C9BF6-EF5A-4B5C-BAD0-AC7253FA7BC2

Q28271235-ECF84ABF-9C17-44B0-BC59-5EA121AA358C

P2860

Q28271235-0084A5BF-B141-4B5C-8BFB-8F84903605D8

Q28271235-0131EF64-99C2-4ADE-ADE1-AB129E91C5E3

Q28271235-0C68D1F2-042E-4970-8E0F-73D7DADEC76D

Q28271235-0D6E2572-9320-45EF-AC4B-34B15F24C65C

Q28271235-0E2D45C3-2E9B-4A5B-962E-9CAE622366C9

Q28271235-0F24B51D-B1FF-4ABF-8471-252CFF026E67

Q28271235-10FAACB6-1036-4BD4-B69F-51B46582165F

Q28271235-11FCF87D-9875-4A07-850F-16FB7149AFE8

Q28271235-1A781660-0299-41E6-8A78-16DBFCC652DB

Q28271235-1C8B401E-7F2D-4DCB-B864-A9B8E5E0B55D

P304

Q28271235-DC0DA390-E79E-4BEB-9994-64F0529DCBA1

P31

Q28271235-DC8AF5F4-B2F2-4A0D-96D8-A23D26A7E523

P3181

Q28271235-C372DF7C-B2D8-499C-A80B-EA60F50C93C1

P356

Q28271235-DC2D5EF4-A7F0-438F-8356-B51079D1C0A1

P407

Q28271235-07DF985E-8102-44CB-A0EA-01BE15030590

P433

Q28271235-4C6BF83C-6580-43F4-A223-961A13E127E1

P478

Q28271235-24430EBF-69D8-4272-90E7-529D6CE8DB35

P577

Q28271235-10F45716-1805-4BFF-A955-78DBA14D6937

P698

Q28271235-A922F5AA-6B81-4767-BC96-B0A707040D7B

P921

Q28271235-7EAD6F42-A496-432F-A0DA-661C3BB1749C

Q28271235-CDFCDAD1-C494-4F74-BBDB-5003A4D40778

P3181

P356

P1433

Human Molecular Genetics

P1476

SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy

@en

P2093

Anja Förster

http://www.w3.org/2001/XMLSchema#string

Bastian Ackermann

http://www.w3.org/2001/XMLSchema#string

Brunhilde Wirth

http://www.w3.org/2001/XMLSchema#string

Eric Hahnen

http://www.w3.org/2001/XMLSchema#string

Ina Fritzsche

http://www.w3.org/2001/XMLSchema#string

Ingmar Blumcke

http://www.w3.org/2001/XMLSchema#string

Jan Hauke

http://www.w3.org/2001/XMLSchema#string

Lutz Garbes

http://www.w3.org/2001/XMLSchema#string

Markus Riessland

http://www.w3.org/2001/XMLSchema#string

Miriam Jakubik

http://www.w3.org/2001/XMLSchema#string

P2860

hnRNP-G promotes exon 7 inclusion of survival motor neuron (SMN) via direct interaction with Htra2-beta1

Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism

Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy.

Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Valproic acid teratogenicity: a toxicogenomics approach

Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy

Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy

Evidence for a modifying pathway in SMA discordant families: reduced SMN level decreases the amount of its interacting partners and Htra2-beta1

The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells

P304

1492-506

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2022313

http://www.w3.org/2001/XMLSchema#string

P356

10.1093/HMG/DDQ023

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2010-04-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20097677

http://www.w3.org/2001/XMLSchema#string

P921

spinal muscular atrophy

maternal health